MCID: SYS041
MIFTS: 23

Systemic Lupus Erythematosus 9

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 9

MalaCards integrated aliases for Systemic Lupus Erythematosus 9:

Name: Systemic Lupus Erythematosus 9 54 71 29
Systemic Lupus Erythematosus, Susceptibility to, 9 13
Sleb9 71

Classifications:



External Ids:

OMIM 54 610927
MedGen 40 C1970455
MeSH 42 D008180

Summaries for Systemic Lupus Erythematosus 9

UniProtKB/Swiss-Prot : 71 Systemic lupus erythematosus 9: A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.

MalaCards based summary : Systemic Lupus Erythematosus 9, also known as systemic lupus erythematosus, susceptibility to, 9, is related to cr2-related susceptibility to systemic lupus erythematosus. An important gene associated with Systemic Lupus Erythematosus 9 is CR2 (Complement C3d Receptor 2). The drugs belimumab and Antibodies have been mentioned in the context of this disorder. Affiliated tissues include bone, skin and kidney.

Description from OMIM: 610927

Related Diseases for Systemic Lupus Erythematosus 9

Symptoms & Phenotypes for Systemic Lupus Erythematosus 9

Clinical features from OMIM:

610927

Drugs & Therapeutics for Systemic Lupus Erythematosus 9

Drugs for Systemic Lupus Erythematosus 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
belimumab Approved Phase 4,Phase 3 356547-88-1 5957 10451420
2 Antibodies Phase 4,Phase 3,Phase 2
3 Heptavalent Pneumococcal Conjugate Vaccine Phase 4,Phase 2,Phase 3
4 Immunoglobulins Phase 4,Phase 3,Phase 2
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
6 Vaccines Phase 4,Phase 2,Phase 3
7 Estrogens Phase 4,Phase 2
8 Estrogens, Conjugated (USP) Phase 4
9 Hormone Antagonists Phase 4,Phase 2
10 Hormones Phase 4,Phase 2
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2
12
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
13 tannic acid Approved, Nutraceutical Phase 3
14 Antibodies, Monoclonal Phase 3,Phase 2
15
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
16
Fulvestrant Approved, Investigational Phase 2 129453-61-8 104741 17756771
17
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
18
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
19
Acetylcysteine Approved, Investigational Phase 1, Phase 2 616-91-1 12035
20 Anticholesteremic Agents Phase 1, Phase 2
21 Antimetabolites Phase 1, Phase 2
22 Atorvastatin Calcium Phase 1, Phase 2 134523-03-8
23 Calcium, Dietary Phase 1, Phase 2
24 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 1, Phase 2
25 Hypolipidemic Agents Phase 1, Phase 2
26 Lipid Regulating Agents Phase 1, Phase 2
27 Antineoplastic Agents, Hormonal Phase 2
28 Estradiol 17 beta-cypionate Phase 2
29 Estradiol 3-benzoate Phase 2
30 Estradiol valerate Phase 2 979-32-8
31 Estrogen Antagonists Phase 2
32 Estrogen Receptor Antagonists Phase 2
33 Polyestradiol phosphate Phase 2
34 Alkylating Agents Phase 2
35 Antifungal Agents Phase 2
36 Anti-Infective Agents Phase 2,Phase 1
37 Antirheumatic Agents Phase 2
38 Calcineurin Inhibitors Phase 2
39 Cyclosporins Phase 2
40 Dermatologic Agents Phase 2
41 glucocorticoids Phase 2
42 Interferon-alpha Phase 2
43 interferons Phase 2
44 Pharmaceutical Solutions Phase 2
45 Antidotes Phase 1, Phase 2
46 Antioxidants Phase 1, Phase 2
47 Antiviral Agents Phase 1, Phase 2
48 Expectorants Phase 1, Phase 2
49 N-monoacetylcystine Phase 1, Phase 2
50 Protective Agents Phase 1, Phase 2

Interventional clinical trials:

(show all 32)

id Name Status NCT ID Phase Drugs
1 A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT01597492 Phase 4
2 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
3 On Open-Label Study in Participants With Systemic Lupus Erythematosus Completed NCT01488708 Phase 3 LY2127399;Placebo
4 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
5 A Study of LY2127399 in Patients With Systemic Lupus Erythematosus Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
6 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
7 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
8 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed NCT01261793 Phase 3 Placebo;Epratuzumab;Epratuzumab
9 A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00424476 Phase 3 Placebo;Belimumab 1 mg/kg;Belimumab 10 mg/kg
10 A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Terminated NCT02041091 Phase 3 Tabalumab Auto-Injector;Tabalumab Prefilled Syringe
11 Study of Epratuzumab in Systemic Lupus Erythematosus (SLE) Terminated NCT00383214 Phase 3 Epratuzumab
12 Study of Epratuzumab in Systemic Lupus Erythematosus Withdrawn NCT00382837 Phase 3 Epratuzumab
13 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors Completed NCT00519363 Phase 1, Phase 2 atorvastatin
14 Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies Completed NCT00417430 Phase 2 ICI 182,780 (Faslodex)
15 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
16 PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus Completed NCT01162681 Phase 2 A-623;A-623;A-623
17 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
18 A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Completed NCT00657189 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;Placebo
19 A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus Recruiting NCT02804763 Phase 2 Placebo;Dapirolizumab pegol (DZP)
20 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE) Active, not recruiting NCT02708095 Phase 2 Baricitinib;Placebo
21 Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine Suspended NCT00775476 Phase 1, Phase 2 N-acetylcysteine;N-acetylcysteine;Placebo
22 Atorvastatin to Prevent Avascular Necrosis of Bone in Steroid Treated Exacerbated Systemic Lupus Erythematosus Terminated NCT00412841 Phase 2 Atorvastatin;Placebo
23 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01686555 Phase 1 ABT-199
24 A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184 Completed NCT01953835 Phase 1 GSK2586184 standard formulation;Simvastatin;Rosuvastatin;GSK2586184 new formulation
25 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Completed NCT02106897 Phase 1 BIIB059;Placebo
26 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
27 Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women Completed NCT00786409
28 Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia Completed NCT01549184
29 Effects of Treatment of Chronic Stress in Patients With Lupus Completed NCT00483613
30 OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis Recruiting NCT02554474
31 Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus. Not yet recruiting NCT02891213
32 Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi) Not yet recruiting NCT02732470

Search NIH Clinical Center for Systemic Lupus Erythematosus 9

Genetic Tests for Systemic Lupus Erythematosus 9

Genetic tests related to Systemic Lupus Erythematosus 9:

id Genetic test Affiliating Genes
1 Systemic Lupus Erythematosus 9 29

Anatomical Context for Systemic Lupus Erythematosus 9

MalaCards organs/tissues related to Systemic Lupus Erythematosus 9:

39
Bone, Skin, Kidney, Bone Marrow

Publications for Systemic Lupus Erythematosus 9

Variations for Systemic Lupus Erythematosus 9

ClinVar genetic disease variations for Systemic Lupus Erythematosus 9:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 CR2 CR2, HAPLOTYPE, TGG single nucleotide variant risk factor

Expression for Systemic Lupus Erythematosus 9

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 9.

Pathways for Systemic Lupus Erythematosus 9

GO Terms for Systemic Lupus Erythematosus 9

Sources for Systemic Lupus Erythematosus 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....